Zion Market Research has published a new report titled “Chemotherapy-Induced Myelosuppression Treatment Market by Indication (Anaemia, Neutropenia and Thrombocytopenia); by Drug Class (Thrombopoietic Agents, Erythropoietin Stimulating Agents, Iron Supplements, Growth Factors and Others); by Route of Administration (Injectable and Oral); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 – 2025”. According to the report, global demand for chemotherapy-induced myelosuppression treatment market was valued at approximately USD 13.81 billion in 2018, and is expected to generate revenue of around USD 17.65 billion by end of 2025, growing at a CAGR of around 3.6% between 2018 and 2025.
Myelosuppression is a term that refers to suppression of bone marrow. Myelosuppression causes reduced blood cells production due to decreased bone marrow activity. This may lead to reduced levels of all blood cells types like platelets, white blood cells (WBCs), red blood cells (RBCs), and any other blood cells. Pancytopenia is a condition that usually arises due to decrease in all three types of blood cells. Chemotherapy’s major side effect is myelosuppression. Chemotherapy may cause to myelosuppression of mild to severe intensity. Medical attention is needed in case of severe myelosuppression which can be even fatal. Different symptoms of myelosuppression are fatigue, shortness of breath, dizziness, dizziness, infection such as cough, fever, chills in case of decrease in white blood cells and anemia in case of decrease in red blood cells etc. Decrease in platelet count may lead to thrombocytopenia.
Request For Free Sample Report @ https://www.zionmarketresearch.com/sample/chemotherapy-induced-myelosuppression-treatment-market
The global demand for chemotherapy-induced myelosuppression treatment market is driven by easy availability of cutting-edge treatment options like chemotherapy, radiotherapy, surgeries, along with growing preference for chemotherapy for treating cancer, growing cancer prevalence across the globe, promising drug pipelines, increasing healthcare expenditure, growing health awareness among patients, launch of cost effective biosimilars and increasing disposable income. However, intense competition and loss of patent exclusivity may act as restraining factors for the market growth in the coming years. Extensive drug pipeline and emphasis by pharmaceutical companies on safe and efficient chemotherapy-induced myelosuppression drugs development are projected to bring new growth avenues for market players during the forecast timeframe.
Based on indication, global chemotherapy-induced myelosuppression treatment market is segmented into anaemia, neutropenia and thrombocytopenia. Market was dominated by neutropenia indication segment in 2018 and is projected to retain its dominance over the forecast timeframe. This is because neutropenia is most common side effect resulting from myelosuppression treatment. Severity and complications of neutropenia may be fatal and thus greater attention is given to avoid neutropenia post myelosuppression treatment and thus attributing to large share. Thrombocytopenia segment will register highest growth over the forecast period.
Based on drug class market is segmented into thrombopoietic agents, erythropoietin stimulating agents, iron supplements, growth factors and others. Market was dominated by growth factors drug class segment 2018. On the other hand erythropoietin stimulating agents segment will register highest growth rate during the forecast period.
Based on route of administration, global market is segmented into injectable and oral. Market was dominated by injectable administration route segment in 2018. This is attributed to their higher therapeutic availability as compared to oral drugs.
The distribution channel segment of the chemotherapy-induced myelosuppression treatment market is categorized into retail pharmacies, hospital pharmacies and online pharmacies. Among all distribution channels, retail pharmacies dominated the market in 2018 with largest revenue share. Online pharmacies are expected to witness rapid growth in the years to come.
North America held largest revenue share of the global chemotherapy-induced myelosuppression treatment market in 2018. This large share is attributed to strong commercial sales, favorable reimbursement policies, large cancer patient pool, growing awareness and presence of key players in this region. Europe was second leading regional market in terms of revenue. Availability of developed infrastructure, increasing cancer prevalence, and growing awareness are major factors that support market growth in this region. Asia Pacific region is projected to be rapidly growing regional market for chemotherapy-induced myelosuppression treatment. Increasing cancer prevalence and geriatric population base, economic development, improvement of healthcare infrastructure, increasing disposable income and healthcare spending, growing awareness are major factors attributing to the swift growth in this region. Moderate growth is projected in Latin America region over the forecast period. Middle East and Africa will witness sluggish growth in the coming years.
Major players in chemotherapy-induced myelosuppression treatment market are Teva Pharmaceutical Industries Ltd., Amgen Inc., Janssen Global Services, LLC, Pfizer Inc., Mylan NV, Mission Pharmacal Company, Myelo Therapeutics GmbH, Dova Pharmaceuticals, Partner Therapeutics, Inc. and Novartis AG among others among others.
The report segment of global chemotherapy-induced myelosuppression treatment market as follows:
Global Chemotherapy-Induced Myelosuppression Treatment Market: Indication
Global Chemotherapy-Induced Myelosuppression Treatment Market: By Drug Class
Global Chemotherapy-Induced Myelosuppression Treatment Market: By Route of Administration
Global Chemotherapy-Induced Myelosuppression Treatment Market: By Distribution Channel
Global Chemotherapy-Induced Myelosuppression Treatment Market: By Region
Inquire more before buying this report @ https://www.zionmarketresearch.com/inquiry/chemotherapy-induced-myelosuppression-treatment-market